MedTrace Logo

Atomoxetine for Treatment of Weight Gain in Olanzapine or Clozapine Patients

NCT00176436 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2022-03-14

Study results available
· View outcomes & findings →

Summary

The study investigates the use of Atomoxetine in combination with exercise and a diet support group (Weight Watchers)to treat weight gain associated with Olanzapine or clozapine. All patients must be adults who have been diagnosed with Schizophrenia or Schizoaffective Disorder.

Conditions

Interventions

BEHAVIORAL

Diet support group

Diet support group weekly and exercise sessions 3 times/week, placebo medication

BEHAVIORAL

Group counseling and exercise

Support group weekly and exercise sessions 3 times/week for 24 weeks

Sponsors & Collaborators

Principal Investigators

  • M Patricia Ball, R.N.,C.,M.S. · University of Maryland Baltimore Maryland Psychiatric Research Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-02-29
Primary Completion
2008-03-31
Completion
2008-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00176436 on ClinicalTrials.gov